JP-2266

JP-2266^[1] is a small-molecule SGLT1/2 dual inhibitor that is designed to help patients with diabetes. It was tested as an adjunct to insulin in type 1 diabetes^[2] and also in patients with type 2 diabetes.^[3] It is reported to be a better drug candidate than sotagliflozin.^[4]

References[edit]

^ "JP 2266 - AdisInsight". adisinsight.springer.com. Retrieved 23 November 2023.
^ Park, Youngjun (1 July 2018). "Antidiabetic Effect of JP-2266, a Novel SGLT1/2 Dual Inhibitor, for the Treatment of Type 1 Diabetes". Diabetes. 67 (Supplement_1). doi:10.2337/db18-2303-PUB. ISSN 0012-1797.
^ "Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients". clinicaltrials.gov. Retrieved 23 November 2023.
^ "Jeil's development of diabetes treatment goes as planned". KBR. 25 June 2018. Retrieved 23 November 2023.

[1] "JP 2266 - AdisInsight". adisinsight.springer.com. Retrieved 23 November 2023.

[2] Park, Youngjun (1 July 2018). "Antidiabetic Effect of JP-2266, a Novel SGLT1/2 Dual Inhibitor, for the Treatment of Type 1 Diabetes". Diabetes. 67 (Supplement_1). doi:10.2337/db18-2303-PUB. ISSN 0012-1797.

[3] "Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients". clinicaltrials.gov. Retrieved 23 November 2023.

[4] "Jeil's development of diabetes treatment goes as planned". KBR. 25 June 2018. Retrieved 23 November 2023.

[1]

[2]

[3]

[4]